Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.50
Bid: 20.50
Ask: 21.00
Change: 0.50 (2.38%)
Spread: 0.50 (2.439%)
Open: 21.50
High: 21.50
Low: 20.75
Prev. Close: 21.00
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing and Issue of Equity

30 May 2018 07:00

RNS Number : 5790P
OptiBiotix Health PLC
30 May 2018
 

30 May 2018

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Placing and Issue of Equity

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes, announces that the Company has raised £1,500,000 through the issue of 2,419,355 new ordinary shares of 2 pence each in the Company ("Ordinary Shares") (together the "Placing Shares") at a price of 62 pence per share.

 

As highlighted in its annual report the Company's cash position remains strong with sufficient funds to deliver on existing plans. However, growing commercial interest in the Company's award winning technology and products have generated new opportunities which if capitalised on have the potential for significant value enhancement. These include:-

 

· The development of the Company's cholesterol and blood pressure reducing strain LPLDL® as a pharmaceutical product. Under existing plans OptiBiotix's products have been developed for the ingredient and supplements market. Following on from the deal with Akums (as announced on 16 May 2018) the Company has received partner interest to license LPLDL® as a pharmaceutical product in the USA and a number of other international markets. Whilst partners will fund regulatory submissions and clinical studies, there is a requirement for OptiBiotix to invest in developing process controls and quality procedures to comply with pharmaceutical production of LPLDL®.

· OptiBiotix reported interest from a number of corporate partners in its SweetBiotix product development (as announced on 27 March 2018). These include manufacturing partners and application developers who want to use SweetBiotix in a wide range of dairy, bread, cereal, and beverage applications. To enable OptiBiotix to meet multiple partner needs and to fully exploit all opportunities additional scientific support is needed to complement the current team.

· The Company has received widespread industry recognition and awards for its SlimBiome® product which has now been incorporated into a wide range of applications. This is part of a process of extending SlimBiome® into a broader range of Health and Wellbeing food and beverage products and attract major retail interest. In order to list SlimBiome® as an own label or branded product in one or more major retailers requires funds to support upfront manufacturing and stocking costs.  

 

Application will be made to the London Stock Exchange to admit the 2,419,355 new Ordinary Shares to trading on AIM. Admission of the Placing Shares is expected to occur on or around 4 June 2018. The Placing Shares will rank pari passu with the existing Ordinary Shares.

 

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 82,905,067 Ordinary Shares. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Stephen O'Hara, CEO of OptiBiotix, said: "The Company has received a high level of partner interest in its technology and products across new application areas and territories that have the potential for significant value uplift. It has become clear that new opportunities, particularly the development of LPLDL® into a pharmaceutical product, the high level of corporate interest in SweetBiotix across multiple applications, and the potential for listing a range of Health and Wellbeing products with major retailers are not achievable in the short term within current resources. Rather than delay these opportunities until OptiBiotix has sufficient revenues to cover costs, the Board has decided to take additional funds to capitalise on these growth opportunities and build shareholder value. Whilst the subscription was oversubscribed the company has limited the funds received to ensure a focus on value creation and has added new institutional investors to the share register."

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Cairn Financial Advisers LLP

Tel: 020 7213 0880

Liam Murray / Jo Turner

finnCap Broker

Tel: 020 7220 0500

Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)

Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOELLFSSEAIAFIT
Date   Source Headline
25th Mar 20247:00 amRNSPlacing, Subscription and Director Dealing
18th Mar 202411:36 amRNSHolding(s) in Company
13th Mar 20247:00 amRNSPartnership agreement with Morepen for SlimBiome
8th Mar 20244:09 pmRNSHolding(s) in Company
27th Feb 20247:00 amRNSStrategic and commercial update
9th Feb 20247:00 amRNSChange of auditor
5th Feb 20247:00 amRNSPresentation at ProBiota 2024
30th Jan 20247:00 amRNSSweetBiotix Update
15th Jan 20247:00 amRNSLaunch of LeanBiome in Muscletech
4th Dec 20237:00 amRNSDirectorate Change
28th Nov 20237:00 amRNSDistribution agreement for SlimBiome
24th Nov 20237:00 amRNSHolding(s) in Company
22nd Nov 20237:00 amRNSBBSRC Grant for WellBiome®
1st Nov 20237:00 amRNSCommercial update
23rd Oct 20237:00 amRNSLicense agreement with Tata Chemicals
19th Oct 20233:02 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSHalf-year Report
22nd Sep 20237:00 amRNSPlanned launch of OptiBiotix products with Boots
29th Aug 20237:00 amRNSCommercial update
31st Jul 202312:51 pmRNSHolding(s) in Company
26th Jul 202312:34 pmRNSResult of AGM
19th Jul 20237:00 amRNSSweetBiotix® overview
28th Jun 20237:00 amRNSFinal Results
4th May 20237:00 amRNSInvestor update
21st Mar 20237:00 amRNSChange of Broker
15th Mar 20237:00 amRNSSlimbiome study results
21st Feb 20237:00 amRNSDirectorate Change
30th Jan 20234:28 pmRNSHolding(s) in Company
5th Dec 20227:00 amRNSIssue of Equity – Subscription
10th Nov 202211:30 amRNSInvestor update
1st Nov 20227:00 amRNSLaunch of GoFigure products on Tmall China
24th Oct 20227:00 amRNSApproval of GoFigure products
17th Oct 20227:00 amRNSNew health claims for SlimBiome in Australia
17th Oct 20227:00 amRNSNew health claims for SlimBiome in Australia
28th Sep 20227:00 amRNSHalf-year Report
26th Sep 20227:00 amRNSLaunch of novel prebiotic in Europe and Africa
20th Sep 20227:00 amRNSLaunch of GoFigure range with Apollo Hospitals
14th Sep 20227:00 amRNSNew commercialisation partner in Asia Pacific
24th Aug 20224:41 pmRNSSecond Price Monitoring Extn
24th Aug 20224:35 pmRNSPrice Monitoring Extension
24th Aug 20222:06 pmRNSSecond Price Monitoring Extn
24th Aug 20222:00 pmRNSPrice Monitoring Extension
24th Aug 202211:06 amRNSSecond Price Monitoring Extn
24th Aug 202211:00 amRNSPrice Monitoring Extension
24th Aug 20229:05 amRNSSecond Price Monitoring Extn
24th Aug 20229:00 amRNSPrice Monitoring Extension
24th Aug 20227:00 amRNSTrading update
26th Jul 202212:31 pmRNSResult of AGM
20th Jul 20227:00 amRNSCommercial and scientific update
11th Jul 20227:00 amRNSJoint development agreement signed with Firmenich

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.